A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
← catalyst calendarNCT07792954 · readout in 563 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
29
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2028-03-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Berobenatide — also filed as PF-08653944
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change From Baseline in Body Weight at Week 48
measured Baseline to Week 48
Related
PFE · their whole pipeline · Obesity readouts · Who in Congress owns PFE? · Executive-branch trades in PFE
PFE's other studiesmost recently updated first
- Safety and Efficacy of Xalkori ROS1 — · Completed
- A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Phase 2 · Completed
- Tucatinib Continuation Study Phase 4 · Not yet recruiting
- A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases Phase 1/2 · Not yet recruiting
- A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 Phase 1 · Not yet recruiting
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed